stockportfolio.pro
Stocks / GRAL vs TMDX
GRAL vs TMDX
GRAIL, Inc. and TransMedics Group, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| GRAIL, Inc. (GRAL) | TransMedics Group, Inc. (TMDX) | |
|---|---|---|
| Market cap | $2.6B | $2.6B |
| Revenue (latest FY) | $147.17M | $605.49M |
| Net income (latest FY) | $-408.35M | $190.29M |
| Revenue growth (5y CAGR) | 38.4% | 88.2% |
| Net margin | -277.5% | 31.4% |
| Return on equity | -15.8% | 40.2% |
| P/E ratio | — | 17.0 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 2 |
| Positive free cash flow | No | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open GRAL — free Open TMDX — freeFrequently asked questions
Which is bigger, GRAL or TMDX?
GRAIL, Inc. is larger by market capitalization — $2.6B versus $2.6B.
Which grows faster, GRAL or TMDX?
Over the last five fiscal years, TransMedics Group, Inc. grew revenue faster — 88.2%/yr versus 38.4%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.